9 To 11 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.6)
-
Patent number: 8563682Abstract: Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed.Type: GrantFiled: June 24, 2005Date of Patent: October 22, 2013Assignee: Thomas Jefferson UniversityInventors: Hank Wolfe, Scott A. Waldman
-
Publication number: 20130274177Abstract: The present Invention relates to nanopeptides isolated from mammalian colostrums with vaccine like antiviral and immunodulator activity via building body's own immune system and attachment inhibition on the cell surface receptors.Type: ApplicationFiled: March 18, 2013Publication date: October 17, 2013Inventor: Pawan SAHARAN
-
Publication number: 20130274206Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.Type: ApplicationFiled: March 15, 2013Publication date: October 17, 2013Applicant: MUSC Foundation for Research DevelopmentInventor: MUSC Foundation for Research Development
-
Patent number: 8557781Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one alkylated amine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.Type: GrantFiled: October 26, 2007Date of Patent: October 15, 2013Assignee: AMBRX, Inc.Inventors: Zhenwei Miao, Junjie Liu, Thea Norman
-
Patent number: 8557777Abstract: The present invention is directed to prostate specific antigen (PSA) and tumor endothelial marker 8 (TEM8) peptide compositions and methods for treating cancer with the compositions.Type: GrantFiled: March 6, 2012Date of Patent: October 15, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Supriya M. Perambakam, David J. Peace
-
Publication number: 20130266537Abstract: The present application provides compositions and methods useful for treating and diagnosing diseases and disorders associated with moesin activation.Type: ApplicationFiled: October 8, 2011Publication date: October 10, 2013Applicant: SHANGHAI KEXIN BIOTECH CO., LTD.Inventors: Yue Zhang, Jun Bao, Hua Mao, Zhinan Shou, Weina Situ
-
Patent number: 8551939Abstract: The use is claimed of opioid peptides with a novel structure, which in addition to the pharmacophore contain structural elements that interact with neurotensisn receptors. Due to the synergistic interaction with the additional element, an augmented analgesic activity is obtained, capable of being used for an extended period due to decreased drug tolerance induction. These compounds may be of particular use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatoid, gout, neurodegeneration, post-operative or post-accidental lesions, or oncogenic lesions.Type: GrantFiled: June 3, 2009Date of Patent: October 8, 2013Assignee: Instytut Medycyny Doswiadczalnej I KlinicznejInventor: Andrzej Lipkowski
-
Publication number: 20130261066Abstract: The present invention provides peptides and peptide conjugates for treating inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. The peptides are derived from annexin-1, can be acetylated or conjugated to fatty acids, may be linear or cyclic, and may comprise D amino acids. Pharmaceutical compositions and methods of use are also disclosed.Type: ApplicationFiled: August 31, 2011Publication date: October 3, 2013Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORKInventors: Ting Nie, Basil Rigas, Nengtai Ouyang
-
Patent number: 8546339Abstract: Soothing cosmetic or pharmaceutical composition that includes at least one peptide as an active principle that activates human HMG-CoA reductase of general formula (I): R1-(AA)n-X1-Gly-Lys-X2-(AA)p-R2 and is chosen from among sequences SEQ ID NO: 1 to SEQ ID NO: 10, in a physiologically suitable medium is described. This novel peptide is designed to act as a soothing active principle capable of providing a solution to skin sensitivity in a cosmetic composition. The invention further applies to a cosmetic treatment method intended to combat skin irritations.Type: GrantFiled: December 23, 2009Date of Patent: October 1, 2013Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8546338Abstract: We have disclosed dicephalic amphiphiles having peptide sequences as the head groups. We have also disclosed self-assembly hydrogels prepared from the dicephalic peptide amphiphiles. These hydrogels are useful for the encapsulation and delivery of bioactives to a patient.Type: GrantFiled: December 8, 2010Date of Patent: October 1, 2013Assignee: Johnson & Johnson Consumer Companies, Inc.Inventors: Jackie J. Donners, Aruna Nathan
-
Publication number: 20130244946Abstract: Isolated peptides are provided, being less than 20 amino acids in length. The peptides comprising an amino acid sequence GVLYVGSKTREGV (SEQ ID NO: 12) AAATGLVKREE (SEQ ID NO: 13) or GVVAAAEKTKQG (SEQ ID NO: 14), mimetics and/or fragment thereof, the peptides being capable of inhibiting alpha synuclein aggregation. Pharmaceutical compositions comprising same are also provided as well as uses thereof.Type: ApplicationFiled: May 22, 2013Publication date: September 19, 2013Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Ronit SHALTIEL-KARYO, Ehud Gazit
-
Patent number: 8536304Abstract: The invention relates to a tumor-associated peptide containing an amino sequence, which is selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:79 of the enclosed listing. The peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. The invention also relates to the use of the peptides for manufacture of a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.Type: GrantFiled: January 22, 2010Date of Patent: September 17, 2013Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Hans Georg Rammensee, Stefan Stevanovic
-
Publication number: 20130237484Abstract: The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof. According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immuno-genicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.Type: ApplicationFiled: April 25, 2011Publication date: September 12, 2013Applicants: Nanao Intelligent Biomedical Engineering Corporation Co., Ltd., Seoul National University R&DB FoundationInventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee, Jin Sook Suh
-
Patent number: 8529904Abstract: A peptide comprising the amino acid sequence RMFPNAPYL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence CMTWNQMNL or a portion or variant thereof provided that the peptide is not intact human WT-1 polypeptide or a peptide comprising the amino acid sequence HLMPFPGPLL or a portion or variant thereof provided that the peptide is not intact human gata-1 polypeptide, and polynucleotides encoding these peptides. The peptides and polynucleotides are useful as cancer vaccines.Type: GrantFiled: July 6, 2007Date of Patent: September 10, 2013Assignee: Ganymed Pharmaceuticals AGInventors: Hans Josef Stauss, Liquan Gao
-
Patent number: 8530430Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.Type: GrantFiled: May 10, 2010Date of Patent: September 10, 2013Assignee: Oncotherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Patent number: 8524673Abstract: A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.Type: GrantFiled: April 21, 2010Date of Patent: September 3, 2013Assignee: KAI Pharmaceuticals, Inc.Inventor: Mike Tso-ping Li
-
Patent number: 8524664Abstract: The present invention provides methods of treating overproduction of cortisol in a subject by administering to the subject a peptide that antagonizes adrenocorticotropin hormone (ACTH) to block the activation of melanocortin 2 receptors.Type: GrantFiled: June 2, 2011Date of Patent: September 3, 2013Assignee: Colorado Seminary, Which owns and Operates The Univeristy of DenverInventor: Robert M. Dores
-
Publication number: 20130225488Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-1 receptor agonistic activity.Type: ApplicationFiled: September 28, 2007Publication date: August 29, 2013Inventors: Rajesh H. Bahekar, Braj Bhushan Lohray, Vidya Bhushan Lohray, Mukul R. Jain, Kaushik M. Banerjee, Pankaj Ramanbhai Patel
-
Patent number: 8518894Abstract: The present invention provides for novel peptides derived from human milk. In aspects of the invention, the peptides are capable, individually or in combination, of evoking an antioxidative stress response, immunomodulation, anti-inflammatory response and anti-pathogenic response. As such the peptides of the invention may be used in food supplements, milk substitutions, infant formula., mother's milk, parenteral nutrition solutions, cell/tissue/organ storage and perfusion solutions and pharmaceutical formulations.Type: GrantFiled: June 1, 2010Date of Patent: August 27, 2013Inventors: Kenneth James Friel, Apollinaire Tsopmo
-
Patent number: 8518871Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.Type: GrantFiled: October 5, 2011Date of Patent: August 27, 2013Assignee: The Regents of the University of CaliforniaInventors: Tracy Hsu, Samir M. Mitragotri
-
Patent number: 8513185Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).Type: GrantFiled: October 13, 2010Date of Patent: August 20, 2013Inventor: Alexander B. Sigalov
-
Patent number: 8513188Abstract: This invention relates to the use of a cyclic compound of formula (I) wherein A, B independently in each occurrence is alkane-i,j-diyl having k carbon atoms, i and independently j being less than or equal k and k being selected from 1 to 10, wherein said alkane-i,j-diyl (i) may comprise one or more double bonds; (ii) is optionally substituted; and/or (iii) comprises a cycle, wherein the total number of cycles being cyclic sugars in said compound is selected from 0 to 4 and is less than p·(n+m); X,Y independently in each occurrence is a biocompatible functional group comprising at least one oxygen atom or two sulphur atoms; n, m independently of each other are selected from 0 to 20; p is selected from 1 to 10; n+m is equal or greater than 1; and p·(n+m) is selected from 3 to 30; wherein said compound is capable of forming a complex with a protonated primary and/or protonated secondary amino group and/or a protonated guanidinium group for the manufacture of a pharmaceutical or diagnostic composition.Type: GrantFiled: September 27, 2007Date of Patent: August 20, 2013Inventor: Paolo Botti
-
Publication number: 20130210742Abstract: The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic polymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably releases compound (I) or a salt thereof over a long period of time and exerts medicinal effects of compound (I) or a salt thereof over a long period of time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing frequency of administration, is an excellent formulation as a clinical medicine.Type: ApplicationFiled: June 23, 2011Publication date: August 15, 2013Applicant: Takeda Pharmaceutical Company LimitedInventors: Tomomichi Futo, Hikaru Taira, Seitaro Mizukami, Naoyuki Murata
-
Publication number: 20130210709Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., positive and negative allosteric modulators, and allosteric agonists) of the G protein coupled receptor for stromal derived factor 1 (SDF-I), also known as the CX-CR4 receptor. The CXCR4 receptor compounds are derived from the intracellular loops and domains of the CXCR4 receptor. The invention also relates to the use of these CXCR4 receptor compounds and pharmaceutical compositions comprising the CXCR4 receptor compounds in the treatment of diseases and conditions associated with CXCR4 modulation such as bone marrow trans-plantation, chemosensitization, cancer, metastatic disease, inflammatory diseases, HIV infection and stem cell-based regenerative medicine.Type: ApplicationFiled: November 4, 2009Publication date: August 15, 2013Inventors: Thomas J. McMurry, Athan Kuliopulos, Lidija Covic, Boris Tchernychev
-
Publication number: 20130210741Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors.Type: ApplicationFiled: January 29, 2013Publication date: August 15, 2013Applicant: 13 THERAPEUTICS, INC.Inventor: 13 Therapeutics, Inc.
-
Publication number: 20130210748Abstract: Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.Type: ApplicationFiled: April 23, 2013Publication date: August 15, 2013Applicants: Oregon Health & Science University, United States of America, as represented by the U.S. Department of Veterans AffairsInventors: United States of America, as represented by the U.S. Department of Veterans Affairs, Oregon Health & Science University
-
Publication number: 20130210749Abstract: The invention provides novel peptides and constructs. In addition the invention provides methods for carrying compounds across the cell membrane, for antagonizing or destroying X-protein of HBV, treatment and/or management of HBV infection, treatment and/or prevention of HCC, and degradation of a target protein.Type: ApplicationFiled: June 10, 2011Publication date: August 15, 2013Applicant: Auckland Uniservices LimitedInventor: Geoffrey Wayne Krissansen
-
Patent number: 8501689Abstract: The present invention relates to a growth factor-mimicking peptide having an activity of the growth factor, and a composition and a method for improving skin conditions or for treating a wound using the same. The growth factor-mimicking peptides of this invention have identical functions or actions to natural-occurring human growth factor, and much better stability and skin penetration potency than natural-occurring growth factor. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on the treatment, prevention and improvement of diseases or conditions demanding growth factor activities. In addition, excellent activity and stability of the peptides of this invention can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.Type: GrantFiled: March 6, 2009Date of Patent: August 6, 2013Assignee: Caragen Co., Ltd.Inventors: Yong-Ji Chung, Young Deug Kim, Eun Mi Kim, Jun Young Choi
-
Patent number: 8497241Abstract: The present invention relates to a WNT10-derived peptide, a composition for improving hair loss and skin conditions using the same, and a composition for treating a WNT10 signal transduction pathway-related disorder and DKK-1 protein-induced disorder the same. WNT10-derived peptide of the present invention possesses identical or similar activities to natural-occurring WNT10, and has much higher stability and skin penetration potency than natural-occurring WNT10. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss (for example, promotion of hair growth or production of hair), but also has superior efficacies on treatment of a WNT10 signal transduction pathway-related disorder and a DKK-1 protein-induced disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics.Type: GrantFiled: November 24, 2009Date of Patent: July 30, 2013Assignee: Caregen Co., Ltd.Inventors: Young Ji Chung, Eun Mi Kim, Sang Su Song, Kyoung Mi Cho
-
Publication number: 20130189291Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.Type: ApplicationFiled: January 17, 2013Publication date: July 25, 2013Applicant: Oncotherapy Science, Inc.Inventor: Oncotherapy Science, Inc.
-
Publication number: 20130190255Abstract: Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.Type: ApplicationFiled: February 21, 2013Publication date: July 25, 2013Applicant: CMS Peptides Patent Holding Company LimitedInventors: Wai Ming WONG, Kong LAM
-
Publication number: 20130184219Abstract: The invention relates to isolated peptides derived from Oryza sativa Japonica Group, pharmaceutical compositions comprising same, and uses thereof for treating, preventing, ameliorating, and/or delaying the onset of inflammatory and/or neuroinflammatory and/or autoimmune diseases or conditions and in particular multiple sclerosis. The invention further relates to extracts from Oryza sativa Japonica Group and use thereof as a dietary supplement or in a pharmaceutical composition for treating, preventing, ameliorating, and/or delaying the onset of inflammatory, and/or inflammatory, neuroinflammatory and/or autoimmune diseases or conditions. The peptides and the extract of the invention may be used for treating, ameliorating, and/or delaying the onset or preventing multiple sclerosis.Type: ApplicationFiled: June 29, 2010Publication date: July 18, 2013Inventor: Uri Wormser
-
Patent number: 8481494Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.Type: GrantFiled: January 26, 2010Date of Patent: July 9, 2013Inventors: Thomas Schrader, Katrin Hochdörffer, Julia März-Berberich, Luitgard Nagel-Steger, Gal Bitan, Sharmistha Sinha
-
Publication number: 20130172242Abstract: The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.Type: ApplicationFiled: June 16, 2011Publication date: July 4, 2013Applicants: MCGILL UNIVERSITY, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
-
Patent number: 8470766Abstract: The present invention provides novel formulations of a ?PKC inhibitor. The ?PKC inhibitor can be, for example, a peptide. The present invention also discloses a method of preventing acute pulmonary cell injury associated with trauma, ALI or ARDS and a method of inhibiting an inflammatory response in pulmonary cells by inhibiting the activity of ?PKC. The invention also provides a method of treating a pulmonary disease with an aerosol formulation of a ?PKC inhibitor to inhibit neutrophil activity.Type: GrantFiled: June 22, 2009Date of Patent: June 25, 2013Assignees: The Children's Hospital of Philadelphia, The Trustees of the University of PennsylvaniaInventors: Laurie Ellen Kilpatrick, Helen Marie Korchak, Clifford S. Deutschman
-
Publication number: 20130157949Abstract: The present invention relates to new peptides, pharmaceutical composition and cosmetic composition comprising them and their use for wound healing.Type: ApplicationFiled: June 14, 2011Publication date: June 20, 2013Applicant: GENE SIGNAL INTERNATIONAL SAInventors: Salman Al-Mahmood, Sylvie Colin
-
Publication number: 20130149245Abstract: The invention relates to a peptide of 8-50 amino acids comprising the sequence of KAHKKRAD or KARKKHAD, or a cyclic peptide of 8-50 amino acids comprising the sequence of HKKR or RKKH. Also disclosed are methods of using the peptide for detecting, monitoring, or treating cancer.Type: ApplicationFiled: September 20, 2012Publication date: June 13, 2013Applicants: CHILDREN'S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIAInventors: UNIVERSITY OF SOUTHERN CALIFORNIA, CHILDREN'S HOSPITAL LOS ANGLES
-
Patent number: 8461104Abstract: The invention relates to a biodegradable barrier network comprising at least two polypeptides, one being anionic and the other one cationic. The invention also relates to applicators and kits comprising components to be used to create said biodegradable barrier network. The invention also relates to the use of said applicator or kit in therapy, such as in medicine, veterinary medicine and horticulture.Type: GrantFiled: June 24, 2010Date of Patent: June 11, 2013Assignee: Bioactive Polymers ABInventors: Stig Bengmark, Kåre Larsson, Björn Lindman, Roland Andersson
-
Publication number: 20130143824Abstract: The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: October 17, 2012Publication date: June 6, 2013Applicant: Genentech, Inc.Inventor: Genentech, Inc.
-
Publication number: 20130143792Abstract: The present invention describes compositions and methods for treating and preventing non-degenerative neurological diseases and disorders associated with elevated sPLA2 activity as well as cardiovascular diseases using a CHEC peptide to inhibit sPLA2 activity.Type: ApplicationFiled: March 28, 2011Publication date: June 6, 2013Applicant: Philadelphia Health & Education Corporation d/b/a Drexel University College of MedicineInventor: Timothy J. Cunningham
-
Publication number: 20130143791Abstract: The present invention relates to compounds, in particular peptides which are capable of stabilizing barrier functions of epithelium and endothelium. The peptides and other compounds of the present invention are useful in the treatment and prevention of diseases or disorders associated with a localized or systemic breakdown of epithelial and endothelial barrier functions. Particular diseases and disorders to be treated and/or prevented with the peptides or other compounds, methods and uses provided herein are burns, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), ventilator induced lung injury (VILI), systemic inflammatory response syndrome (SIRS), acute kidney injury (AKI), sepsis, multiorgan dysfunction syndrome (MODS), or edema.Type: ApplicationFiled: June 17, 2011Publication date: June 6, 2013Applicant: XiberScience GmbHInventors: Peter Petzelbauer, Sonja Reingruber
-
Patent number: 8455616Abstract: The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.Type: GrantFiled: March 6, 2008Date of Patent: June 4, 2013Assignee: National Center for Global Health and MedicineInventors: Yukihito Ishizaka, Masakatsu Hasegawa, Satoshi Nohara
-
Publication number: 20130136742Abstract: Provided are transmembrane complexes that contain a protein transduction domain (PTD) from the N-terminus of IgE-dependent histamine-releasing factor (HRF) and a target substance that is to be delivered into a cell. Also provided are nucleic acid molecules encoding the transmembrane complex, and methods of delivering the target substance into a cell interior by contacting the transmembrane complex with a cell. Also provided are transfection kits containing the PTD and the target substance.Type: ApplicationFiled: February 1, 2013Publication date: May 30, 2013Inventors: Kyunglim LEE, Youngjoo Kwon, Miyoung Kim, Moonhee Kim
-
Patent number: 8450283Abstract: The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer.Type: GrantFiled: September 10, 2009Date of Patent: May 28, 2013Assignee: National Taiwan UniversityInventors: Pan-Chyr Yang, Tse-Ming Hong, Yuh-Ling Chen, Ang Yuan, Yi-Ying Wu
-
Patent number: 8450285Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media.Type: GrantFiled: June 4, 2010Date of Patent: May 28, 2013Assignee: 13Therapeutics, Inc.Inventors: Sharon L. McCoy, Steven H. Hefeneider
-
Patent number: 8450279Abstract: The present invention discloses cell permeable Nm23 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a metastasis suppressor Nm23. Also disclosed are polynucleotides encoding the cell permeable Nm23 recombinant proteins, an expression vector containing the cell permeable Nm23 recombinant protein, and a pharmaceutical composition for preventing metastasis which contains the cell permeable Nm23 recombinant protein as an effective ingredient. The cell permeable Nm23 recombinant proteins of the present invention can induce KSR phosphorylation and inactivation and inhibit Ras-mediated MAPK cascade by efficiently introducing a metastasis suppressor Nm23 into a cell. Therefore, the cell permeable Nm23 recombinant proteins of the present invention can be effectively used as an anti-metastatic agent capable of preventing cancer metastasis by inhibiting the proliferation, differentiation and migration of cancer cells.Type: GrantFiled: September 4, 2008Date of Patent: May 28, 2013Assignee: Procell Therapeutics Inc.Inventors: Daewoong Jo, Thi Thuy Nga Do, Kisuk Park
-
Publication number: 20130130996Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.Type: ApplicationFiled: January 28, 2013Publication date: May 23, 2013Applicant: Biokine Therapeutics Ltd.Inventor: Biokine Therapeutics Ltd.
-
Publication number: 20130129759Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.Type: ApplicationFiled: June 27, 2012Publication date: May 23, 2013Applicant: Oncotherapy Science, Inc.Inventors: Tomoaki Fujioka, Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Midori Shida
-
Patent number: 8445449Abstract: Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.Type: GrantFiled: October 23, 2012Date of Patent: May 21, 2013Assignees: The United States of America, as represented by the Department of Veterans Affairs, Oregon Health & Science UniversityInventors: Steven H. Hefeneider, Sharon L. McCoy
-
Patent number: 8445441Abstract: A purified polypeptide for inhibiting binding of BCL-2 to IP3 receptors includes an amino acid sequence consisting of about 10 to 80 amino acids. The amino acid sequence has a sequence identity at least 90% homologous to a portion of SEQ ID NO:1. The polypeptide inhibits binding of Bcl-2 to IP3 receptors of cells that express IP3R and Bcl-2 and induces apoptosis in a cell.Type: GrantFiled: August 26, 2011Date of Patent: May 21, 2013Assignee: Case Western Reserve UniversityInventors: Clark W. Distelhorst, Yiping Rong